Crescita Therapeutics Sees Strong Q3 Revenue Growth
Company Announcements

Crescita Therapeutics Sees Strong Q3 Revenue Growth

Story Highlights

Crescita Therpeutc (TSE:CTX) has released an update.

Crescita Therapeutics reported a revenue increase of 18.5% in Q3 2024, driven by growth in its Skincare segment and higher licensing revenue. The company is also enhancing its manufacturing capabilities with new equipment and a long-term agreement with a major client, aiming to boost profitability and secure a new partner for Pliaglis in the U.S.

For further insights into TSE:CTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskCrescita Therapeutics Positions for Growth Amid Q2 Challenges
TipRanks Canadian Auto-Generated NewsdeskCrescita Therapeutics Secures Lucrative Manufacturing Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App